<DOC>
	<DOCNO>NCT00577577</DOCNO>
	<brief_summary>To investigate effect rhIGF-I/rhIGFBP-3 treatment 24 week endurance , ambulation , cognitive functioning , insulin resistance , lipid level , muscle function strength , pain , gastrointestinal functioning , quality life endpoint DM1 patient</brief_summary>
	<brief_title>Safety Efficacy Study Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 ( rhIGF-I/rhIGFBP-3 ) In Myotonic Dystrophy Type 1</brief_title>
	<detailed_description>Efficacy Measures : Endurance , Ambulation , Cognitive function , Insulin resistance , Cholesterol triglycerides , Muscle function strength , Pain , Gastrointestinal function , Quality life MINIMUM INCLUSION CRITERIA 1 . A diagnosis DM1 , confirm DM1 genetic mutation 2 . Age 21 65 year ( inclusive ) 3 . Ability walk 30 foot - assistance cane and/or leg bracing permit 4 . Able self-administer study medication subcutaneous injection caregiver available administer study medication</detailed_description>
	<mesh_term>Myotonic Dystrophy</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Inclusion Criteria ( list inclusive ) : A diagnosis DM1 , confirm DM1 genetic mutation Ability walk 30 foot assistance cane and/or leg bracing permit Able selfadminister study medication subcutaneous injection caregiver available administer study medication Exclusion Criteria ( list inclusive ) : Congenital DM1 Weight great 100 kg body mass index great 30 kg/m2 Prior treatment glucocorticoid , anabolic steroid , testosterone , growth hormone , investigational agent within 60 day screen Current diagnosis history malignancy expect surgically cured skin cancer pilomatricoma Changes lipid lower medication 3 month prior screen Diaphragmatic weakness patient unable tolerate supine position , swallow impairment patient unable maintain nutrition without use gastrostomy . Major psychiatric illness ( major depression , bipolar disorder schizophrenia ) within twelve month screen History noncompliance therapy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>